[go: up one dir, main page]

WO2002013759A3 - Methode de traitement du syndrome du diabete de type ii humain - Google Patents

Methode de traitement du syndrome du diabete de type ii humain Download PDF

Info

Publication number
WO2002013759A3
WO2002013759A3 PCT/US2001/022466 US0122466W WO0213759A3 WO 2002013759 A3 WO2002013759 A3 WO 2002013759A3 US 0122466 W US0122466 W US 0122466W WO 0213759 A3 WO0213759 A3 WO 0213759A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
syndrome
treating
type
opiates
Prior art date
Application number
PCT/US2001/022466
Other languages
English (en)
Other versions
WO2002013759A2 (fr
Inventor
Anton H Clemens
Original Assignee
Cpd Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpd Llc filed Critical Cpd Llc
Priority to EP01953517A priority Critical patent/EP1365756A2/fr
Priority to AU2001275959A priority patent/AU2001275959A1/en
Publication of WO2002013759A2 publication Critical patent/WO2002013759A2/fr
Publication of WO2002013759A3 publication Critical patent/WO2002013759A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'un humain souffrant du syndrome du diabète de type II. Cette méthode consiste à administrer, selon un mode efficace sur le plan pharmacologique, une composition médicamenteuse comprenant des opiacés possédant une activité agoniste ν.
PCT/US2001/022466 2000-08-15 2001-07-17 Methode de traitement du syndrome du diabete de type ii humain WO2002013759A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01953517A EP1365756A2 (fr) 2000-08-15 2001-07-17 Methode de traitement du syndrome du diabete de type ii humain
AU2001275959A AU2001275959A1 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of type 2 diabetes in humans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63893000A 2000-08-15 2000-08-15
US09/638,930 2000-08-15

Publications (2)

Publication Number Publication Date
WO2002013759A2 WO2002013759A2 (fr) 2002-02-21
WO2002013759A3 true WO2002013759A3 (fr) 2003-07-10

Family

ID=24562030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022466 WO2002013759A2 (fr) 2000-08-15 2001-07-17 Methode de traitement du syndrome du diabete de type ii humain

Country Status (3)

Country Link
EP (1) EP1365756A2 (fr)
AU (1) AU2001275959A1 (fr)
WO (1) WO2002013759A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100469500B1 (ko) 2002-06-29 2005-02-02 엘지전자 주식회사 이동통신단말기의 송수신장치
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
WO2008051902A2 (fr) * 2006-10-20 2008-05-02 Cpd, Llc Procédé pour rétablir l'effet de l'incrétine
EP2561866A1 (fr) * 2011-08-26 2013-02-27 Heinrich-Heine-Universität Düsseldorf Dérivés de morphinane pour traiter les diabètes et troubles associés
EP2747754B1 (fr) * 2011-08-26 2017-04-05 Deutsche Diabetes-Forschungsgesellschaft e. V. Dérivés de morphinane pour traiter le diabètes et des troubles associés
WO2016073615A1 (fr) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Sels et compositions utiles pour le traitement de maladie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059997A1 (fr) * 1998-05-18 1999-11-25 Novo Nordisk A/S Nouvelles 1,3,8-triazaspiro[4.5]decanones possedant une affinite elevee pour les sous-types du recepteur opioide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059997A1 (fr) * 1998-05-18 1999-11-25 Novo Nordisk A/S Nouvelles 1,3,8-triazaspiro[4.5]decanones possedant une affinite elevee pour les sous-types du recepteur opioide

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AHLGREN, GUNNAR: "Insulin -like action of morphine and certain morphine derivatives", XP002222946, retrieved from STN Database accession no. 24:20275 HCA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GREEN, I. C. ET AL: "Opioid peptide effects on isolated hepatocytes and islets of Langerhans", XP002222947, retrieved from STN Database accession no. 105:203461 HCA *
DATABASE MEDLINE [online] August 1980 (1980-08-01), GREEN I C ET AL: "Effect of enkephalins and morphine on insulin secretion from isolated rat islets.", XP002222945, Database accession no. NLM6998819 *
DATABASE MEDLINE [online] January 1987 (1987-01-01), BAILEY C J ET AL: "Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice.", XP002222948, Database accession no. NLM3032718 *
DIABETOLOGIA. GERMANY, WEST AUG 1980, vol. 19, no. 2, August 1980 (1980-08-01), pages 158 - 161, ISSN: 0012-186X *
DIABETOLOGIA. GERMANY, WEST JAN 1987, vol. 30, no. 1, January 1987 (1987-01-01), pages 33 - 37, ISSN: 0012-186X *
INTERNATIONAL CONGRESS SERIES (1986), 700(DIABETES 1985), 258-62 *
LIU I M ET AL: "Activation of opioid mu-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats.", NEUROSCIENCE LETTERS. IRELAND 23 APR 1999, vol. 265, no. 3, 23 April 1999 (1999-04-23), pages 183 - 186, XP001108832, ISSN: 0304-3940 *
SKAND, ARCH. PHYSIOL (1930), 58, 153-72 *

Also Published As

Publication number Publication date
AU2001275959A1 (en) 2002-02-25
EP1365756A2 (fr) 2003-12-03
WO2002013759A2 (fr) 2002-02-21

Similar Documents

Publication Publication Date Title
WO2003026635A3 (fr) Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains
HUP0102658A2 (hu) Opioid agonista és opioid antagonista hatóanyag-kombinációt tartalmazó gyógyszerkészítmény
Bickel et al. Buprenorphine treatment of opioid dependence: a review.
CA2312234A1 (fr) Utilisation du methylnaltrexone et composes afferents a ce compose
WO2002013801A3 (fr) Methode amelioree permettant de traiter les facteurs de risque de cardiopathie ischemique chez les humains
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
JP2004512260A5 (fr)
US20030026838A1 (en) Tamper-proof narcotic delivery system
WO2000001377A2 (fr) Sels et bases de la molecule de 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol destines a optimiser l'homeostase de la dopamine pendant l'administration d'analgesiques opioides
CA2446738A1 (fr) Forme posologique d'opioides empechant la consommation abusive
WO2003070191A8 (fr) Dispositifs inviolables d'administration transdermique d'opioide
US20100227876A1 (en) Methods of Reducing Side Effects of Analgesics
WO2009120889A3 (fr) Formulations transdermiques inviolables d’agonistes et d’agonistes-antagonistes d’opiacés
US20070185145A1 (en) Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2004045551A3 (fr) Composition pharmaceutique
WO1999011250A3 (fr) Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie
WO2003032990A3 (fr) Conjugues polymeres d'antagonistes opioides
RU2005113996A (ru) Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции
RU2000119778A (ru) Комбинации агонист/антагонист опиоида
WO2004000354A3 (fr) Procede de traitement du syndrome de la lipodystrophie
WO2001041705A3 (fr) Traitement et prevention de vertiges et prurits
WO2001042207A3 (fr) Nouvelles methodes de traitement et de prevention de l'occlusion intestinale
O’Neill et al. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice
WO2002013759A3 (fr) Methode de traitement du syndrome du diabete de type ii humain
RU2012124063A (ru) Лекарственная комбинация с теобромином и ее использование в лечении

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001953517

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001953517

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001953517

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP